WSO - April 2024 - 406

1217670
WSO
International Journal of StrokeNaftali et al.
Research
Lung cancer is associated with acute
ongoing cerebral ischemia:
A population-based study
Jonathan Naftali1*
, Rani Barnea1,2*, Ruth Eliahou2,3,
Keshet Pardo1, Assaf Tolkovsky1, Meital Adi4,
Vadim Hasminski2,3, Walid Saliba5,6, Sivan Bloch6,7,
Guy Raphaeli1,2, Avi Leader2,8 and Eitan Auriel1,2
International Journal of Stroke
2024, Vol. 19(4) 406 -413
© 2023 World Stroke Organization
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/17474930231217670
journals.sagepub.com/home/wso
https://doi.org/10.1177/17474930231217670
Abstract
Background and Objectives: Cerebral microinfarcts (CMIs) are the most common type of brain ischemia; however,
they are extremely rare in the general population. CMIs can be detected by magnetic resonance diffusion-weighted imaging
(MRI-DWI) only for a very short period of approximately 2 weeks after their formation and are associated with an
increased stroke risk and cognitive impairment. We aimed to examine CMI detection rate in patients with lung cancer
(LC), which is strongly associated with ischemic stroke risk relative to other cancer types.
Methods: We used the Clalit Health Services record (representing more than 5 million patients) to identify adults with
LC and breast, pancreatic, or colon cancer (non-lung cancer, NLC) who underwent brain magnetic resonance diffusion
(MRI) scan within 5 years following cancer diagnosis. All brain MRI scans were reviewed, and CMIs were documented,
as well as cardiovascular risk factors.
Results: Our cohort contained a total of 2056 MRI scans of LC patients and 1598 of NLC patients. A total of 143 CMI
were found in 73/2056 (3.5%) MRI scans of LC group compared to a total of 29 CMI in 22/1598 (1.4%) MRI scans of
NLC (p < 0.01). Cancer type (e.g. LC vs NLC) was the only associated factor with CMI incidence on multivariate analysis.
After calculating accumulated risk, we found an incidence of 2.5 CMI per year in LC patients and 0.5 in NLC.
Discussion: CMIs are common findings in cancer patients, especially in LC patients and therefore might serve as a
marker for occult brain ischemia, cognitive decline, and cancer-related stroke (CRS) risk.
Keywords
Magnetic resonance diffusion-weighted imaging, antithrombotic, lesions, MRI, acute, cerebral infraction, ischemic stroke,
radiology, stroke subtypes
Received: 29 June 2023; accepted: 9 November 2023
1Department of Neurology, Rabin Medical Center, Petach Tikva, Israel
2Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
3Department of Radiology, Rabin Medical Center, Petach Tikva, Israel
4Department of Radiology, Kaplan Medical Center, Rehovot, Israel
5Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel
6Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
7Department of Neurology, Lady Davis Carmel Medical Center, Haifa, Israel
8Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel
*Equal contribution.
Corresponding author:
Eitan Auriel, Department of Neurology, Rabin Medical Center, Zeev Jabotinsky Street 39, Petah Tikva 49100, Israel.
Email: eitanur@clalit.org.il
International Journal of Stroke, 19(4)
http://www.sagepub.com/journals-permissions https://www.doi.org/10.1177/17474930231217670 http://journals.sagepub.com/home/wso

WSO - April 2024

Table of Contents for the Digital Edition of WSO - April 2024

Content
WSO - April 2024 - Cover1
WSO - April 2024 - Cover2
WSO - April 2024 - 373
WSO - April 2024 - Content
WSO - April 2024 - 375
WSO - April 2024 - 376
WSO - April 2024 - 377
WSO - April 2024 - 378
WSO - April 2024 - 379
WSO - April 2024 - 380
WSO - April 2024 - 381
WSO - April 2024 - 382
WSO - April 2024 - 383
WSO - April 2024 - 384
WSO - April 2024 - 385
WSO - April 2024 - 386
WSO - April 2024 - 387
WSO - April 2024 - 388
WSO - April 2024 - 389
WSO - April 2024 - 390
WSO - April 2024 - 391
WSO - April 2024 - 392
WSO - April 2024 - 393
WSO - April 2024 - 394
WSO - April 2024 - 395
WSO - April 2024 - 396
WSO - April 2024 - 397
WSO - April 2024 - 398
WSO - April 2024 - 399
WSO - April 2024 - 400
WSO - April 2024 - 401
WSO - April 2024 - 402
WSO - April 2024 - 403
WSO - April 2024 - 404
WSO - April 2024 - 405
WSO - April 2024 - 406
WSO - April 2024 - 407
WSO - April 2024 - 408
WSO - April 2024 - 409
WSO - April 2024 - 410
WSO - April 2024 - 411
WSO - April 2024 - 412
WSO - April 2024 - 413
WSO - April 2024 - 414
WSO - April 2024 - 415
WSO - April 2024 - 416
WSO - April 2024 - 417
WSO - April 2024 - 418
WSO - April 2024 - 419
WSO - April 2024 - 420
WSO - April 2024 - 421
WSO - April 2024 - 422
WSO - April 2024 - 423
WSO - April 2024 - 424
WSO - April 2024 - 425
WSO - April 2024 - 426
WSO - April 2024 - 427
WSO - April 2024 - 428
WSO - April 2024 - 429
WSO - April 2024 - 430
WSO - April 2024 - 431
WSO - April 2024 - 432
WSO - April 2024 - 433
WSO - April 2024 - 434
WSO - April 2024 - 435
WSO - April 2024 - 436
WSO - April 2024 - 437
WSO - April 2024 - 438
WSO - April 2024 - 439
WSO - April 2024 - 440
WSO - April 2024 - 441
WSO - April 2024 - 442
WSO - April 2024 - 443
WSO - April 2024 - 444
WSO - April 2024 - 445
WSO - April 2024 - 446
WSO - April 2024 - 447
WSO - April 2024 - 448
WSO - April 2024 - 449
WSO - April 2024 - 450
WSO - April 2024 - 451
WSO - April 2024 - 452
WSO - April 2024 - 453
WSO - April 2024 - 454
WSO - April 2024 - 455
WSO - April 2024 - 456
WSO - April 2024 - 457
WSO - April 2024 - 458
WSO - April 2024 - 459
WSO - April 2024 - 460
WSO - April 2024 - 461
WSO - April 2024 - 462
WSO - April 2024 - 463
WSO - April 2024 - 464
WSO - April 2024 - 465
WSO - April 2024 - 466
WSO - April 2024 - 467
WSO - April 2024 - 468
WSO - April 2024 - 469
WSO - April 2024 - 470
WSO - April 2024 - 471
WSO - April 2024 - 472
WSO - April 2024 - 473
WSO - April 2024 - 474
WSO - April 2024 - 475
WSO - April 2024 - 476
WSO - April 2024 - 477
WSO - April 2024 - 478
WSO - April 2024 - Cover3
WSO - April 2024 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com